|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma
Title: | Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma |
Authors: | Yang, Zijian Browse this author | Suda, Goki Browse this author →KAKEN DB | Maehara, Osamu Browse this author | Ohara, Masatsugu Browse this author | Yoda, Tomoka Browse this author | Sasaki, Takashi Browse this author | Kohya, Risako Browse this author | Yoshida, Sonoe Browse this author | Hosoda, Shunichi Browse this author | Tokuchi, Yoshimasa Browse this author | Kitagataya, Takashi Browse this author | Suzuki, Kazuharu Browse this author | Kawagishi, Naoki Browse this author | Nakai, Masato Browse this author | Sho, Takuya Browse this author | Natsuizaka, Mitsuteru Browse this author | Ogawa, Koji Browse this author | Ohnishi, Shunsuke Browse this author | Sakamoto, Naoya Browse this author →KAKEN DB |
Keywords: | resistance | mechanism | immune checkpoint inhibitor | atezolizumab | bevacizumab | hepatocellular carcinoma | progressive disease | VEGF-D | angiopoietin-2 |
Issue Date: | Feb-2023 |
Publisher: | MDPI |
Journal Title: | Cancers |
Volume: | 15 |
Issue: | 3 |
Start Page: | 593 |
Publisher DOI: | 10.3390/cancers15030593 |
Abstract: | Simple Summary The possible mechanisms of resistance to atezolizumab/bevacizumab for unresectable HCC and the subsequent response to these therapies remain underexplored. The sequential changes in serum growth factors, including VEGF-A, VEGF-C, VEGF-D, ANG-2, FGF-19, HGF, and EGF during atezolizumab/bevacizumab for unresectable HCC were evaluated in 46 patients. Of 32 patients with disease control, 28 experienced PD after CR, PR, or SD with atezolizumab/bevacizumab. Growth factor changes between the baseline and best overall response points (BOR) for patients with disease control showed that FGF-19 significantly increased and ANG2 significantly decreased at the BOR. Growth factor changes between the BOR and the PD point in 28 patients who experienced PD after disease control showed that VEGF-D and ANG2 significantly increased at the PD point compared with that at the BOR. Summarily, increased serum VEGF-D and ANG-2 levels might contribute to developing resistance to atezolizumab/bevacizumab for unresectable HCC and might be target molecules in subsequent salvage therapies. The possible mechanisms of resistance to atezolizumab/bevacizumab for unresectable HCC, and the subsequent response to these therapies, remain underexplored. The sequential changes in serum growth factors, including VEGF-A, VEGF-C, VEGF-D, ANG-2, FGF-19, HGF, and EGF during atezolizumab/bevacizumab for unresectable HCC were evaluated in 46 patients. Patients who experienced PD after CR, PR, or SD to atezolizumab/bevacizumab were evaluated. A total of 4, 9, 19, and 14 patients showed CR, PR, SD, and PD, respectively. Of 32 patients with disease control, 28 experienced PD after CR, PR, or SD with atezolizumab/bevacizumab. Baseline growth factor levels were similar between patients with or without disease control and those with or without an objective response. Growth factor changes between the baseline and the best overall response points (BOR) for patients with disease control showed that FGF-19 significantly increased and ANG2 significantly decreased at the BOR. Growth factor changes between the BOR and the PD point in 28 patients who experienced PD after disease control showed that VEGF-D and ANG2 significantly increased at the PD point compared with that at the BOR. Summarily, increased serum VEGF-D and ANG-2 levels might contribute to developing resistance to atezolizumab/bevacizumab for unresectable HCC and might be target molecules in subsequent salvage therapies. |
Type: | article |
URI: | http://hdl.handle.net/2115/89182 |
Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|